Inhibrx has been granted a patent for fusion proteins combining serpin polypeptides with Fc, cytokine targeting, WAP domain containing, or albumin polypeptides. The patent covers therapeutic and diagnostic applications, as well as methods of production. GlobalData’s report on Inhibrx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Inhibrx Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Inhibrx, Personalized cancer vaccines was a key innovation area identified from patents. Inhibrx's grant share as of April 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Fusion protein with aat and hsa polypeptides

Source: United States Patent and Trademark Office (USPTO). Credit: Inhibrx Inc

A recently granted patent (Publication Number: US11965017B2) discloses an isolated fusion protein that includes at least one alpha-1 antitrypsin (AAT) polypeptide linked to a human serum albumin (HSA) polypeptide. The fusion protein, as described in the patent claims, follows a specific amino acid sequence outlined in SEQ ID NO: 30 or 31. This fusion protein is designed for inhibiting or downregulating aberrant serine protease expression or activity in individuals requiring such intervention.

The patent further details a method for administering the isolated fusion protein to individuals, particularly humans, who may be suffering from various diseases or disorders. These conditions include but are not limited to alpha-1 antitrypsin (AAT) deficiency, respiratory ailments like emphysema and chronic obstructive pulmonary disease (COPD), inflammatory conditions such as rheumatoid arthritis and Crohn's disease, as well as infectious diseases like pneumonia and sepsis. The method also encompasses scenarios involving ischemia-reperfusion injury, autoimmune disorders like systemic lupus erythematosus, and neurological conditions such as multiple sclerosis. Additionally, the patent specifies that the fusion protein can be utilized in cases of bacterial, fungal, or viral infections, showcasing its broad potential applications in the medical field.

To know more about GlobalData’s detailed insights on Inhibrx, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies